

03 July 2025

Treatment of Oncology Breast Cancer

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies?

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) <5
- Abemaciclib + Fulvestrant 7
- Alpelisib + Fulvestrant <5
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide <5
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel 8
- Atezolizumab <5
- Capivasertib <5
- Capecitabine as a single agent 30
- Carboplatin + Paclitaxel <5
- Elacestrant <5
- Eribulin as a single agent or in combination 5
- Everolimus + Exemestane <5
- Fulvestrant as a single agent 20
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) <5
- Palbociclib + Fulvestrant 9
- Parp Inhibitors (Olaparib/Talazoparib) <5
- Pembrolizumab Monotherapy <5
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab <5
- Carboplatin + Paclitaxel + Pembrolizumab <5
- Pertuzumab (Perteja) + Trastuzumab (Herceptin) <5
- Phesgo (Pertuzumab + Trastuzumab in a single injection) 8
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) <5
- Ribociclib + Fulvestrant <5
- Sacituzumab Govitecan 6
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 8
- Trastuzumab deruxtecan (Enhertu) 13
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel 22
- Trastuzumab emtansine (Kadcyla) 19

03 July 2025

- Any other active systemic anti-cancer therapy See list below**
- Aromatase Inhibitor as a single agent <5

**

Atezolizumab + Nab-Paclitaxel <5
Capivasertib + Fulvestrant <5
Abemaciclib 58
Acceler EC <5
Carboplatin AUC6 <5
D-Phesgo 10
DC-Phesgo <5
EC-D 37
ECDPhesgo 26
EC-Pac/Carbo 6
ECP Phesgo <5
FEC Weekly P <5
FECD Phesgo <5
Goserelin 5
Neratinib <5
Palbociclib 61
Pegylated Dox <5
Pembro Pac <5
Ribociclib 38
TucatCapTras 7
Vinorelbine 5
WklyPac Phesgo <5
Zol Acid 13

Where numbers are low, we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

03 July 2025

2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part

Title acronym	Full Title	TOTAL recruitment June 2025	Target
SMALL	A Phase III, randomised, multi-centre trial addressing overtreatment of small, screen-detected breast cancer by comparing standard surgery with minimally invasive vacuum-assisted excision	35	50
ATNEC	Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy	5	10
EndoNET	Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine therapy in post-menopausal women	<5	10
HER2-RADICAL	The HER2-RADICAL study (Response Adaptive Care Plan) - Tailoring treatment for HER2 positive early breast cancer	<5	5